Target intelligence / Profile preview

Herpes simplex virus DNA primase (UL52) (UL52)

Target
UL52
Molecular classification
Enzyme, DNA primase, Viral replication protein
01

Overview

The Herpes simplex virus DNA primase (UL52) is the primase subunit of the heterotrimeric helicase-primase complex, which also includes the UL5 helicase and the UL8 scaffold protein [2, 11]. This complex is essential for viral DNA replication, where UL52 is responsible for synthesizing short RNA primers on the lagging strand to initiate DNA synthesis by the viral DNA polymerase [11, 13]. UL52 interacts extensively with UL5 and UL8 to coordinate the unwinding of double-stranded DNA and the subsequent primer synthesis at the replication fork [5, 13]. As a therapeutic target, UL52 is inhibited by a novel class of antiviral drugs known as helicase-primase inhibitors (HPIs), including pritelivir and amenamevir [1, 3, 10]. These inhibitors bind to the complex and stabilize its interaction with the DNA template, effectively halting the progression of the replication fork [2, 4, 24]. Because HPIs do not require activation by viral thymidine kinase and target a different mechanism than traditional nucleoside analogues like acyclovir, they are effective against drug-resistant HSV strains [1, 3, 14].

Other names
UL52pUL52HSV DNA primaseHerpes simplex virus type 1 protein UL52Herpes simplex virus type 2 protein UL52HSV-1 UL52HSV-2 UL52Primase subunit UL52
02

Mechanism of action

Helicase-primase inhibition; stabilization of the viral helicase-primase complex on DNA to prevent unwinding and primer synthesis [2, 4, 21, 24].

03

Biological functions

Viral DNA replicationRNA primer synthesisDNA unwindingCoordination of leading and lagging strand synthesis
04

Disease associations

InfectionHerpes simplex virus infectionGenital herpesCold sores
05

Safety considerations

Antiviral resistance [4, 9, 12]Thrombocytopenia [10]Gingival bleeding [10]Palpitations [10]Drug-drug interactions (CYP3A4 metabolism) [8]
06

Interacting drugs

Pritelivir

5 more in the full profile.

07

Biomarkers

Viral DNA load [6, 10]UL52 resistance mutations (e.g., A899, A906) [4, 9, 12]Lesion healing time [1, 10]

Beyond the preview

Go deeper on Herpes simplex virus DNA primase (UL52) (UL52).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herpes simplex virus DNA primase (UL52) (UL52).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call